Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

DENVER -- The two-drug combination of doravirine and islatravir was as efficacious as the three-drug regimen of bictegravir, ...

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.

IMPAACT 2017 (MOCHA) week 96 results show long-acting Cabenuva (cabotegravir + rilpivirine) effectively maintained viral suppression in 94.4% of adolescents aged 12 to <18 years Additional paediatric ...

A new once-daily HIV pill combining doravirine and islatravir shows strong safety and effectiveness, offering a promising alternative to existing therapies Researchers at Queen Mary University of ...

The table below is a review of notable updates that occurred in November 2025 for investigational products in development (not an inclusive list). Click on the status ...

A Q&A With Rajesh Gandhi, MD. GANDHI: The main reasons patients and their clinicians consider switching are to simplify treatment, reduce drug interactions, and mitigate long-term safety risks. In my ...

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...

HIV Virus Creative artwork featuring colorized 3D prints of HIV virus particles. The virus surface (red) is covered with proteins (dark blue) that enable the virus to enter and infect human cells, and ...

Nucleoside reverse transcriptase inhibitor exposure is significantly associated with a reduced risk for subsequent development of Alzheimer disease, reinforcing the idea that inflammasome inhibition ...